^
Association details:
Biomarker:KRAS G12S
Cancer:Colorectal Cancer
Drug:sunitinib (Multi-tyrosine kinase inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer

Excerpt:
In the MTT chemosensitivity assay, the grade of resistance was less pronounced in G13D and highest in G12A, G12C, and G12S mutant cells.
DOI:
10.1007/s00432-013-1401-9